Results 321 to 330 of about 304,614 (388)

Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.

Chest, 2013
BACKGROUND Treprostinil is a stable prostacyclin analog approved for the treatment of pulmonary arterial hypertension (PAH) as parenteral or inhaled therapy.
V. Tapson, Z. Jing, Kaifeng Xu, L. Pan, J. Feldman, D. Kiely, E. Kotlyar, C. McSwain, K. Laliberte, C. Arneson, Lewis J. Rubin   +10 more
semanticscholar   +1 more source

Endothelin Receptor Antagonists

2013
Three pathways have been identified in the pathogenesis of pulmonary arterial hypertension (PAH): the endothelin (ET), nitric oxide (NO) and prostacyclin pathways. These pathways represent the targets of approved PAH therapies and their discovery has facilitated significant progress in the understanding and treatment of PAH.
Alessandro Maresta, Marc Humbert, Marc Humbert, Martine Clozel   +3 more
openaire   +3 more sources

Endothelin receptor antagonist for subarachnoid haemorrhage

Cochrane Database of Systematic Reviews, 2010
A subarachnoid hemorrhage (SAH) is a serious and potentially life-threatening condition where blood leaks out of blood vessels over the surface of the brain. Delayed ischemic neurological deficit (DIND) and the related feature of vasospasm, where patients experience a delayed deterioration, have long been recognized as the leading potentially treatable
Lei Jiang, Kehu Yang, Jia Guo, Jin Hui Tian, Zhenghong Shi   +4 more
openaire   +4 more sources

Endothelin receptor antagonists

World Journal of Urology, 2005
Hormone refractory prostate cancer remains true to its middle name: it is largely refractory to attempts to delay its progression. New targets and new therapies are demanded. Through a review of the available literature on endothelin and several preclinical observations, the endothelin axis has emerged as one such target.
openaire   +3 more sources

Endothelin, endothelin receptors, and endothelin antagonists

Current Opinion in Nephrology and Hypertension, 1994
Endothelin is a peptide with potent biologic effects in vascular and nonvascular cells. Its effects are mediated by two receptors, ETA and ETB, and possibly also by a third receptor, ETC. In vascular smooth muscle cells, endothelin causes profound contraction and also has proliferative effects, mainly through activation of ETA but also through ETB ...
openaire   +3 more sources

Thiophenesulfonamides as endothelin receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 1996
AbstractChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 100 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.
Adam Kois, Raju Bore Gowda, Fiona Stavros, Ming Fai Chan, Erik Verner, Ilya Okun, Chengde Wu   +6 more
openaire   +3 more sources

Bosentan: a dual endothelin receptor antagonist

Expert Opinion on Investigational Drugs, 2002
The peptide endothelin plays a significant role in a wide array of pathological conditions, including primary pulmonary hypertension and pulmonary arterial hypertension associated with collagen vascular disease. These are life-threatening conditions that can severely compromise the function of the lungs and heart.
Sébastien Roux, Lewis J. Rubin
openaire   +2 more sources

Enrasentan, an Antagonist of Endothelin Receptors

Cardiovascular Drug Reviews, 2003
ABSTRACTEndothelins are powerful vasoconstrictor agents produced by endothelial cells and identified by Yanagisawa et al. in 1988. Two types of receptors for endothelins have been identified: ETAreceptors are located on smooth muscle cells of the vascular wall and are responsible for endothelin‐induced vasoconstriction while ETBreceptors are located on
openaire   +4 more sources

Bis-sulfonamides as endothelin receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2003
Modification of the structure of bosentan 1, the first marketed endothelin receptor antagonist (Tracleer), by introduction of a second sulfonamide function at the alkoxy side chain, led to bis-sulfonamides 2. This allowed to prepare dual ET(A)/ET(B) as well as ET(B) receptor selective antagonists, which could serve as tools to investigate the ...
Martin Bolli, Martine Clozel, Walter Fischli, Christoph Boss, Thomas Weller   +4 more
openaire   +3 more sources

Endothelin Receptor Antagonists

2015
Endothelin-1 (ET-1) is a potent vasoconstrictor and mitogen that is secreted by the endothelium. Pulmonary vascular expression of endothelin is increased in pulmonary hypertension and plasma levels correlate with the severity of disease. Several endothelin receptor antagonists (ERAs) have been developed and are available for the treatment of pulmonary ...
Richard N. Channick, Josanna Rodriguez-Lopez   +1 more
openaire   +2 more sources